Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Major Depressive Disorder
Phase EARLY_PHASE1
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: Ketamine — A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
  • Other: Placebo — A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.

Primary Outcomes

  • Change in glutamate concentration in the medial prefrontal cortex (mPFC) (Baseline, 24 hours post-infusion, 14 days post-infusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2022-11-08
Completion: 2028-03-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Michael Treadway, PhD (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Michael Treadway, PhD
(404) 727-7541
ketaminestudy@emory.edu
Michael Treadway, PhD
(404) 727-7541
ketaminestudy@emory.edu
Emory University
Michael Treadway, PhD
Emory University
Interventions
  • Drug: Ketamine — A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
  • Other: Placebo — A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
Study Locations (1 sites)
Emory University, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: MDD Patients: * willing and able to give written informed consent * men or women, 18-65 years of age * primary diagnosis of DSM-V MDD, current, as diagnosed by the SCID-I * score of ≥20 on the Beck Depression Inventory, which will include patients characterized as having "moderate/severe" (20-28) or "very-severe" (29-63) depressive symptoms * off all antidepressant therapy for at least 8 weeks prior to the baseline visit Healthy Controls: * willing and able to give written informed consent * men or women, 18-65 years of age Exclusion Criteria: MDD Patients: * history of any bipolar disorder or psychotic disorder * active psychotic symptoms of any type * substance abuse/dependence within 6 months of study entry (as determined by SCID) * unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination and laboratory testing), including upper respiratory disease or asthma, glaucoma or porphyria. * active suicidal ideation as determined by a score ≥3 on the Columbia Suicide Severity Rating Scale (C-SSR) * use of any recreational drugs as confirmed by urine drug screen at the time of scanning * pregnancy or lactation * use of glucocorticoids at any time during the study * Raynaud's disease that may interfere with the cold-pressor * contraindications for MRI * MMSE score \<28 * elevated blood pressure prior to infusion (systolic \> 160 or diastolic \>100) * history of treatment resistance as determined by ATRQ * prior adverse reaction to ketamine * use of antipsychotic medications * use of greater than 2mg daily of lorazepam or similar benzodiazipine. * Regular smoker as self-reported Healthy Controls: * evidence of any psychiatric disorder with exception of specific phobia, and no history of any psychiatric disorder except mild past substance use disorder as diagnosed by the SCID-I * history of any substance abuse within the last 6 months * use of any recreational drugs as confirmed by urine drug screen at the time of scanning * pregnancy or lactation * use of glucocorticoids at any time during the study * Raynaud's disease that may interfere with the cold-pressor * contraindications for MRI * MMSE score \<28 * Regular smoker as self-reported
Conditions Depression, Psychosis, Anhedonia
Phase PHASE4
Enrollment 103
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Transdermal Estradiol — Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
  • Drug: Micronized Progesterone — Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
  • Drug: Matching Placebo Patch — Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
  • Drug: Raclopride C11 — All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Primary Outcomes

  • Changes in Striatal Activation Between Groups during the MID task (Baseline (week 3) to Endpoint (week 7))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-04-20
Completion: 2026-12-31
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 103 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Crystal E Schiller, PhD (PRINCIPAL_INVESTIGATOR) - UNC School of Medicine - Department of Psychiatry
  • Gabriel Dichter, PhD (PRINCIPAL_INVESTIGATOR) - UNC School of Medicine - CIDD
Contact Information
Study Contact:
Kathryn G Gibson, BS
919-966-5243
kathryn_gibson@med.unc.edu
Laura C Lundegard, BA
919-966-5243
laura_lundegard@med.unc.edu
Laura C Lundegard, BA
919-966-5243
laura_lundegard@med.unc.edu
University of North Carolina at Chapel Hill
Interventions
  • Drug: Transdermal Estradiol — Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
  • Drug: Micronized Progesterone — Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
  • Drug: Matching Placebo Patch — Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
  • Drug: Raclopride C11 — All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
Study Locations (1 sites)
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514 United States
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures, lifestyle considerations, and availability for the duration of the study * 44-55 years old unmedicated perimenopausal women who have ≥ 2 skipped menstrual cycles, amenorrhea ≥ 60 days, corresponding to the late menopause transition (Stages of Reproductive Aging Workshop (STRAW stage -1). * Anhedonia or psychosis symptoms that began during the period of menstrual irregularity. * Clinician's Global Impression Scale-Severity score (CGI-S) \> 3 to confirm a clinically impaired sample. * Anhedonia severity inclusion criteria and stratification: All participants will have Snaith-Hamilton Pleasure Scale (SHAPS) scores \> 20 consistent with the NIMH Fast-Fail Trial for Mood and Anxiety Disorders, corresponding to clinically impairing anhedonia. * Psychosis severity inclusion criteria and stratification: Participants will be stratified according to scores on the psychotic subscale of the Brief Psychiatric Rating Scale (BPRS) * Willingness to adhere to the estradiol regimen Exclusion Criteria: * Pregnancy; allergies to any active or inactive ingredients in the Climara® patch or Prometrium®. * BMI \< 18 or \> 35 kg/m\^2 * A history of chronic menstrual cycle irregularity, meaning \> 1 year without menses * MR contraindications: Metal in the body, dental work other than fillings or gold, tattoos, metal injury, any other implant unless they are 100% plastic. * PET contradictions: participation in \>1 research study in the past 12 months that included ionizing radiation exceeding 3 rem to the whole body (e.g., PET, CT). Standard of care imaging is not exclusionary. * The use of psychotropics or hormonal preparations. * History of psychiatric illness during the 2 years before the onset of perimenopause. * History of chronic, recurrent mood or psychotic disorders (i.e., more than one non-reproductive-related mood episode prior to the perimenopausal index episode). * A history of mood episodes requiring hospitalization. * Current mania; * Depressive episode(s) within 2 years of enrollment not associated with the transition to menopause; * A history of suicide attempts within the last year or current active suicidal ideation with intent and plan. * Neurological conditions (e.g., history of seizure or TBI) * Brain stimulation treatment in the past six months. * Endometriosis; * First degree relative with premenopausal breast cancer or breast cancer presenting in both breasts or multiple family members (greater than three relatives) with postmenopausal breast cancer. * Current medication use (i.e., current psychotropics, current anti-hypertensives, current statins, current hormonal preparations, or frequent use of anti-inflammatory agents (\> 10 times/month)). Women will be allowed to enroll who take medications without known mood effects (e.g. stable thyroid hormone replacement and occasional (\< 5 times/month) use of Ambien)\*; * Pregnant, breastfeeding or trying to conceive; * Last menstrual period more than 12 months prior to enrollment; * History of undiagnosed vaginal bleeding; * Undiagnosed enlargement of the ovaries; * Polycystic ovary syndrome; * History of breast or ovarian cancer; * First degree relative with ovarian cancer; * Abnormal finding in a provider breast exam and/or mammogram; * Known carrier of BRCA1 or 2 mutation; * Porphyria; * Malignant melanoma; * Hodgkin's disease; * Recurrent migraine headaches that are preceded by aura; * Gallbladder or pancreatic disease\*\*; * Heart or kidney disease\*\*; * Liver disease; * cerebrovascular disease (stroke); * First degree relative with history of heart attack or stroke; * Current nicotine use; * Self-reported claustrophobia * Peanut allergy * all reported prescription medications will be reviewed and cleared by a study physician prior to a participant's enrollment; * participants will be given the opportunity to describe these conditions in the online screening survey. Reported conditions that are acute in nature and/or benign will be reviewed by a study physician and exclusions will be decided case-by-case. All chronic conditions will be exclusionary. For those where it is deemed that an exclusion does not apply, primary analyses will not be affected, but exploratory analyses will be conducted excluding these individuals
Conditions Breast Neoplasms, Neoplastic Cells, Circ...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without adjuvant chemotherapy. The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the prognosis of breast cancer patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Diagnostic Test: CTC detection — CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.

Primary Outcomes

  • iDFS (From date of enrollment through study completion, up to 10 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-03-01
Completion: 2029-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hunan Cancer Hospital
Contact Information
Study Contact:
Quchang Ouyang
+8673189762161
oyqc1969@126.com
Quchang Ouyang, PhD
+86 13973135318
Oyqc1969@126.com
Hunan Cancer Hospital
Quchang Ouyang, PhD
Hunan Cancer Hospital
Interventions
  • Diagnostic Test: CTC detection — CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
Study Locations (1 sites)
Hunan Cancer Hospital, Changsha, Hunan 410006 China
Eligibility Criteria
Inclusion Criteria * The age is more than 18 years old; * Pathology confirmed malignant breast tumor; * No clinical diagnosis of other malignancies, unstable complications or uncontrolled infection; * Life expectancy is greater than 6 month; * The main organ function is normal; * The subjects volunteered to participate in this study, signed informed consent, followed up with good compliance. Exclusion Criteria * Patients who had suffered from other malignant tumors; * With uncontrolled bacterial, viral or fungal infections; * With physical or mental disorders * Without or limited civil capacity; * Infected with human immunodeficiency virus (HIV); * Circumstances in which the investigator considers it inappropriate to participate in this study.

Cardiometabolic Screening Program

NCT05386719
Recruiting
Conditions Breast Cancer, Early-stage Breast Cancer
Phase NA
Enrollment 450
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors. This program will also help to direct individuals with risk factors to community and institutional resources for management.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: Prescreening — Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status \& questions about cardiovascular disease.
  • Other: Screening and Enrollment — Consent
  • Behavioral: Baseline — Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review
  • Behavioral: Interpret BMI — Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention
  • Other: Interpret HbA1c — HbA1c results categorized as follows: HbA1c \<5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication
  • Other: Interpret lipid panel and assess other risk factors — Based on above categories: HbA1c \<5.7%: Any of these cardiovascular disease risk factors: current/former tobacco use, total cholesterol \>200, family history of Coronary Artery Disease/Heart Attack in first degree family \<55 year old male or \<65 year old female, systolic blood pressure \>130 HbA1c 5.7-6.4%: Refer to Primary Care Provider and consider Healthful Eating, Activity and Weight Program (HEAWP) HbA1c 6.5%+: Refer to Endocrinology if HbA1c ≥8% Known diabetic on medication: Refer to Endocrinology if HbA1c ≥7%
  • Behavioral: Assess 10 year risk of cardiovascular event — If risk factors are present - refer to Cardiovascular Disease Prevention Program
  • Behavioral: Recommendations — Provide individual patient handout based on all above interventions

Primary Outcomes

  • Prevalence of prediabetes (3 years)
  • Prevalence of diabetes (3 years)
  • Prevalence of hyperlipidemia (3 years)
  • Change in HbA1c (Baseline, 6 months, 12 months)
  • Change in LDL cholesterol (Baseline, 6 months, 12 months)
  • Prevalence of obesity/ overweight (Baseline, 6 months, 12 months)
  • Quality of Life Questionnaire The European Organisation for Research and Treatment Cancer C30 (Baseline, 6 months, 12 months)
  • Breast-specific symptoms assessed by the of The European Organisation for Research and Treatment Cancer Quality of Life Questionnaire BR-23 (Baseline, 6 months, 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-06-03
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Private Philanthropic Funds
Principal Investigators:
  • Jennifer Sheng, M.D. (PRINCIPAL_INVESTIGATOR) - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact Information
Study Contact:
Hopkins Breast Trials
410-614-1361
HopkinsBreastTrials@jhmi.edu
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
410-955-8804
jhcccro@jhmi.edu
Vered Stearns, MD
443-287-6547
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Interventions
  • Other: Prescreening — Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status \& questions about cardiovascular disease.
  • Other: Screening and Enrollment — Consent
  • Behavioral: Baseline — Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review
  • Behavioral: Interpret BMI — Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention
  • Other: Interpret HbA1c — HbA1c results categorized as follows: HbA1c \<5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication
Study Locations (1 sites)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of early stage breast cancer * Completed local and/or systemic therapy at least 3 months ago * Receiving medical oncology care at through the breast cancer clinics at Johns Hopkins Medical Institute, including the Sidney Kimmel Comprehensive Cancer Center in Baltimore MD and Green Spring Station in Lutherville-Timonium MD, and Sibley Memorial Hospital in Washington D.C. * Read and speak English Exclusion Criteria: * Metastatic breast cancer
Conditions Type 2 Diabetes
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine the effects THC has on Glucose Metabolism and Endothelial Functioning in participants with Type 2 Diabetes. The participants will complete blood tests and tests to measure energy expenditure, CVD risks, and glucose metabolism. These tests will be performed prior to start of treatment and again after 2-weeks of treatment with the THC or placebo.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: THC — 2-Week, once daily, flexible dose, inhaled THC
  • Drug: Placebo — 2-Week, once daily, flexible dose, inhaled placebo

Primary Outcomes

  • Change in Glucose Disposal Rate (6 weeks)
  • Change in Vascular Endothelial Function (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-08-22
Completion: 2028-06
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Collaborators: Center for Medicinal Cannabis Research
Contact Information
Study Contact:
Todd May, MS
858-246-2169
tmay@health.ucsd.edu
Todd May, MS
t1dresearch@health.ucsd.edu
UC San Diego Altman Clinical & Translational Research Institute
Jeremy Pettus, MD
UC San Diego Altman Clinical & Translational Research Institute
Interventions
  • Drug: THC — 2-Week, once daily, flexible dose, inhaled THC
  • Drug: Placebo — 2-Week, once daily, flexible dose, inhaled placebo
Study Locations (1 sites)
UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California 92037 United States
Eligibility Criteria
Inclusion Criteria: * Males and Females 21-70 years old at the time of screening. * Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study. * Male subjects must be willing to use clinically acceptable method of contraception during the entire study. * Have a clinical diagnosis of Type 2 Diabetes on a stable medication regimen for at least 3 months. * BMI \> 25 kg/m2). * HbA1c \< 10%). * Negative urine toxicology result at screening visit. * Able to provide written informed consent approved by an Institutional Review Board (IRB). Exclusion Criteria: * History or presence of any clinically significant illness, as detected by history, physical examination, and/or laboratory tests, that might put the participant at increased risk of adverse events (e.g., history of psychotic disorder, clinically significant mood and/or anxiety disorder, liver, or renal disease). * No prior history of myocardial infarction, stroke or heart failure. * Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion. * Hemoglobin \< 9g/dL. * Liver enzymes ≥ 2 times upper normal limit and/or clinical signs/symptoms consistent with liver disease, including but not limited to nausea, vomiting, jaundice, itching, abdominal pain, or edema. * History of clinically significant adverse events associated with cannabis intoxication (e.g., severe anxiety and panic, paranoia and psychosis, sustained tachycardia, or severe hypotension). * History of seizures, head trauma, or other history of CNS insult that could predispose the participant to seizures. * Use of any THC containing products within 30 days prior to the screening visit. * Current use of tobacco products. * Individuals who are pregnant or lactating/breastfeeding. * Current use of insulin to treat Type 2 Diabetes. * Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits. * Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent.
Conditions Sarcoma, Synovial, Sarcoma,Soft Tissue, ...
Phase PHASE1, PHASE2
Enrollment 3
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CYCLOPHOSPHAMIDE and FLUDARABIN — 1\. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
  • Drug: Cyclophosphamide — CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
  • Biological: HBI 0201-ESO TCRT — HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
  • Drug: Aldesleukin — Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.

Primary Outcomes

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (5 years)
  • objective tumor regression (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2022-04-01
Completion: 2027-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hadassah Medical Organization
Principal Investigators:
  • Michal Lotem, MD (PRINCIPAL_INVESTIGATOR) - Hadassah Medical Organization
Contact Information
Study Contact:
Michal Lotem, Prof.
+972058573528
mlotem@hadassah.org.il
Yafit Halutsi
+972526906339
yafitha@hadassah.com
Michal Lotem, Prof.
+972508573528
mlotem@hadassah.org.il
Hadassah Medical Organization
Interventions
  • Drug: CYCLOPHOSPHAMIDE and FLUDARABIN — 1\. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
  • Drug: Cyclophosphamide — CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
  • Biological: HBI 0201-ESO TCRT — HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
  • Drug: Aldesleukin — Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
Study Locations (1 sites)
Hadassah Medical Organization, Jerusalem, 9112001 Israel
Eligibility Criteria
Inclusion Criteria: 1. Have histologically or cytologically confirmed diagnosis of neoplasia 2. Measurable (per RECIST v1.1 criteria) metastatic cancer or locally advanced refractory/recurrent malignancy not amenable to curative treatment. Lesions previously irradiated may be considered measurable only if growth has been documented since local treatment completion. 3. The tumor expresses ESO as assessed immunohistochemistry of resected tissue. To this end, archived tumor tissue suitable for analysis must be available or re-biopsy performed on study. Tissue staining must encompass more than 10% of tumor section. 4. Patients must have previously either (1) received at least first-line or second-line standard therapy for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease), intolerable or have recurred or (2) Recurred within 6 months of adjuvant systemic therapy known to be active also in the metastatic setting. 5. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible. 6. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). 7. Age ≥ 18 years and ≤ 70 years. 8. Patient is able to understand and willing to sign a written informed consent. 9. Clinical performance status of ECOG 0, 1 or 2. 10. HLA-A\*0201or A\*0206 positive. 11. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment. 12. Women of child-bearing potential must have a negative pregnancy test. 13. Serology: Seronegative for HIV antibody, hepatitis B antigen, and hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative. 14. Hematology * ANC \> 1500/mm3 without the support of filgrastim * WBC ≥ 3000/mm3 * Platelet count ≥ 100,000/mm3 * Hemoglobin \> 8.0 g/dL. Subjects may be transfused to reach this cut-off. 15. Chemistry * Serum ALT/AST ≤ 2.5 x ULN * Creatinine clearance ≥40ml/min * Total bilirubin ≤ 1.5 mg/dL, except in patients with Gilbert's Syndrome, who must have a total bilirubin \< 3.0 mg/dL. * INR \< 1.5 Exclusion Criteria: 1. Women of child-bearing potential who are pregnant or breastfeeding. 2. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease). 3. Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses 4. Concurrent systemic steroid therapy, not including replacement therapy or treatment with prednisone up to 10mg daily or its equivalent. Or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention. 5. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin. 6. Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within 3 months. 7. Subjects unable to maintain normal oxygen saturation level in room air. 8. Subjects who have had a venous thromboembolic event requiring anticoagulation and who meet any of the following criteria: * Have been on a stable dose of anticoagulation for \< 1 month (except for acute line insertion induced thrombosis). * Have had a Grade 2, 3, or 4 hemorrhage in the last 30 days or are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement). 9. Has a known additional malignancy within the last 3 years. Exceptions include early stage cancers (carcinoma in situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy). 10. LVEF ≤ 40% 11. Documented FEV1 ≤ 60% predicted tested in patients with: * A prolonged history of cigarette smoking (≥ 20 pack-year smoking history, with cessation within the past two years). * Symptoms of respiratory dysfunction. 12. Patients who are at the time of study initiation receiving any other investigational agents. 13. Carcinomatosis meningitis or other brain involvement exceeding that allowed above. 14. Has received live vaccine within 30 days before the first dose of study intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
Conditions Type2Diabetes, ASCVD
Phase PHASE4
Enrollment 6000
Locations 36 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will be followed for the occurrence of the trial primary endpoint of the total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, counting all events from randomization until end of study.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: SGLT2 inhibitor — Empagliflozin, dapagliflozin, or canagliflozin
  • Drug: GLP-1 receptor agonist — Dulaglutide, liraglutide, semaglutide

Primary Outcomes

  • Total (first and recurrent) cardiovascular, kidney, and death events (Through study completion, with an average follow up of approximately 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-09-26
Completion: 2029-03-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 6000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Collaborators: Patient-Centered Outcomes Research Institute
Contact Information
Study Contact:
Brendan Everett, MD, MPH
617-732-8790
PRECIDENTDccc@bwh.harvard.edu
Maureen Malloy
617-732-8773
PRECIDENTDccc@bwh.harvard.edu
Jeff Dunlap
256-489-2879
jdunlap@longwoodresearch.net
Longwood Research LLC
Interventions
  • Drug: SGLT2 inhibitor — Empagliflozin, dapagliflozin, or canagliflozin
  • Drug: GLP-1 receptor agonist — Dulaglutide, liraglutide, semaglutide
Study Locations (36 sites)
Longwood Research LLC, Huntsville, Alabama 35801 United States
HonorHealth Research & Innovation Institute, Scottsdale, Arizona 85258 United States
Eastside Clinical Research Associates, Los Angeles, California 90022 United States
Kendall South Medical Center, Inc, Miami, Florida 33185 United States
South Florida Research Solutions, LLC, Pembroke Pines, Florida 33028 United States
NSC Research, Inc., Johns Creek, Georgia 30024 United States
Herman Clinical Research, Suwanee, Georgia 30024 United States
University of Illinois Chicago, Chicago, Illinois 60612 United States
Rush University Medical Center, Hinsdale, Illinois 60521 United States
University of Iowa, Iowa City, Iowa 52242 United States
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes based on clinical diagnosis * HbA1c ≥6% measured within 12 months prior to screening * Secondary prevention cohort (at least 70% of cohort): * Age 40 to 80 years * Evidence of established atherosclerotic cardiovascular disease (ASCVD), as defined by one or more of the following * Coronary heart disease defined by at least one of the following: prior myocardial infarction, prior coronary percutaneous coronary intervention, ≥50% stenosis of a coronary artery documented by invasive or non-invasive imaging (including CT coronary angiography), positive stress test, or coronary artery calcium score \>400 Agatston units; * Cerebrovascular disease defined by at least one of the following: prior ischemic stroke, prior carotid revascularization procedure, carotid stenosis ≥ 50% documented by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound; * Symptomatic peripheral artery disease defined by at least one of the following: leg symptoms with an ABI ≤ 0.9, leg symptoms with imaging evidence of a stenosis ≥50% in a peripheral artery documented by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound, or prior amputation for atherosclerotic disease. * Primary prevention cohort (capped at 30% of cohort): * Age 60-80 years and at least 1 additional high-risk feature: * Cardiovascular risk factors/high-risk features: * Active smoking (combustible tobacco or marijuana) * HbA1c ≥ 8% measured within 12 months prior to screening. The most recent value available at the time of screening will be used for screening and to determine eligibility. * Stage 3a CKD, eGFR 45-59 ml/min/1.73m2 measured within 12 months prior to screening. The most recent value available at screening will be used for screening and to determine eligibility. * Willingness to be randomly assigned to medication class (SGLT2i or GLP-1 RA or both) and fill prescription through personal pharmacy benefit while having other medications adjusted for safety * Willingness to avoid starting a therapy in the alternative treatment group (e.g., if randomized to GLP-1 RA, avoid starting an SGLT2i) unless strongly recommended by the participant's usual care provider. * If taking one of the study medication classes, willingness to stop SGLT2i or GLP-1 RA and be randomly assigned to one of the two medication classes * Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities Exclusion Criteria: * Known or suspected diabetes of other cause (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.) * Any background diabetes medication regimen will be allowed in this pragmatic trial with the following proviso: o Participants taking basal-bolus, prandial, or multiple daily injection insulin (MDI) regimens (e.g., short-acting in combination with long-acting insulin, called MDI regimens) are eligible only if the research staff attests that there has been communication with the usual diabetes care provider and that the provider has agreed to manage insulin adjustment with initiation of study medications. If such agreement has not been obtained, participants taking MDI regimens are excluded. * History of diabetic ketoacidosis * Active diabetic foot ulcer * History of pancreatitis * Heart failure as a primary reason for hospitalization within the past year * Known left ventricular ejection fraction \<40% * Known urinary albumin-to-creatinine ratio \>200 mg/g at screening * Estimated glomerular filtration rate (eGFR) less than 45 ml/min/1.73m2 measured within 12 months prior to screening. The most recent value available at screening will be used for screening and to determine eligibility. * Known inability to afford study medication through current insurance coverage. * If a woman of child-bearing potential, the patient or partner is unwilling to use birth control * Active treatment for cancer, planned treatment for cancer, or recent active cancer with likelihood of recurrence or progression, which, in the opinion of the site investigator, has a likelihood of recurrence that would interfere with study therapy prior to 2028 * Treated cancer with no evidence of disease, no evidence of disease progression, and no planned change in therapy is allowed. Examples of allowable cancers include: * Breast cancer stable after active treatment, managed with long-term anti-estrogen therapy * Prostate cancer being observed * Stage 0 or 1 tumors status post resection or other definitive treatment * Other similarly stable cancer comorbidities * History of solid organ or bone marrow transplant * Allergy to SGLT2 inhibitor or GLP-1 receptor agonist
Conditions Hypertension, Self-Management, Technolog...
Phase NA
Enrollment 208
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension (HTN) has a greater impact on African Americans (AA) than any other U.S. racial group. Uncontrolled blood pressure (BP) contributes to higher rates of disability, death, and health resource use among AA. HTN is the single most influential risk factor for cardiovascular disease (CVD), as well as a risk factor for the incidence of stroke, diabetes, chronic kidney disease, and dementia. Importantly, older adults account for 15% of the U.S. population, and two-thirds of older adults over age 60 have HTN, with higher rates observed in AA older adults. Strategies to support self-managing HTN and BP control are crucial as the older population is projected to age considerably and become more racially and ethnically diverse. Research has documented the negative effects on health and health outcomes of poorly controlled BP and is one of the most important modifiable CVD risk factors. Lower BP targets will require aggressive management and an increase in antihypertensive medications. Therefore, to achieve lower targets in this population, greater efforts, including patient-centered methods will be needed to support self-managing HTN, especially in terms of medication adherence. As we shifted into the digital age, the use of mHealth technologies (smart phones, applications, SMS or text messaging) has been a powerful approach and mechanism for the treatment and management of chronic diseases. However, behavioral interventions that incorporate technology do not reach minorities or disadvantaged AA older adults with HTN. OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP) will leverage existing knowledge of effective technology-based components for HTN self-management to support and improve BP control using unique aspects of mHealth platforms in AA older adults. Findings from this study, if confirmed, will improve BP control and support self-managing HTN, as well as has the potential to close the health disparity gap between AA and non-AA older adults with HTN.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: OPTIMA-BP Intervention — Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention: 1. Six weekly web-based education sessions on hypertension management. 2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months. 3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months. 4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress. 5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor.

Primary Outcomes

  • Blood Pressure Control (Baseline - 6 months)
  • Health Related Quality of Life (HRQOL) (Baseline - 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-02-14
Completion: 2027-05-31
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 208 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Case Western Reserve University
Collaborators: University Hospitals Cleveland Medical Center
Principal Investigators:
  • Carolyn Still, PhD (PRINCIPAL_INVESTIGATOR) - Case Western Reserve University, School of Nursing
Contact Information
Study Contact:
Carolyn Still, PHD
216-368-6338
carolyn.still@case.edu
Carolyn Still
216-368-6338
cwh11@case.edu
Case Western Reserve University
Mahbooh Rahman, MD
216-844-3798
Case Western Reserve University
Interventions
  • Behavioral: OPTIMA-BP Intervention — Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention: 1. Six weekly web-based education sessions on hypertension management. 2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months. 3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months. 4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress. 5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor.
Study Locations (1 sites)
Case Western Reserve University, Cleveland, Ohio 44143 United States
Eligibility Criteria
Inclusion Criteria: 1. Self-identify as African American 2. 50 years of age or older 3. Diagnosed with hypertension, with a systolic blood pressure≥ 130 mmHg but less than 170 mmHg 4. Prescribed at least two hypertensive, one of which is a diuretic/thiazide and or calcium channel blocker antihypertensive medication 5. Own a smartphone with a data plan, the capability to download the Medisafe app, or view videos 6. Able to read/understand English Exclusion Criteria: 1. Unable to give informed consent or judged to have impaired cognitive ability or severe memory 2. Currently using a medication management application (app) 3. Experienced a major CVD event or procedure (e.g., myocardial infarction, stroke, heart surgery) within the past year 4. Patients with a diagnosis of chronic kidney disease (defined as estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73m2) and/or receiving dialysis.
Conditions Suicidal Ideation, Treatment-resistant D...
Phase NA
Enrollment 76
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective clinical trial to confirm the effectiveness of bilateral accelerated theta burst stimulation (aTBS) on suicidal ideation (SI), while exploring cortical inhibition measures in this treatment paradigm. In this proposed study, the investigators will evaluate the anti-suicidal effects of bilateral aTBS over the DLPFC compared to accelerated intermittent theta burst stimulation (aiTBS) over the left DLPFC in participants with TRD and SI. Additionally, the investigators aim to identify neurophysiological targets through which bilateral aTBS induces remission of SI in TRD differentially from aiTBS.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Accelerated Theta Burst Stimulation — B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.

Primary Outcomes

  • Changes in scores on the suicide scale index (SSI) from baseline (6-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-09-02
Completion: 2030-07-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 76 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Collaborators: National Institutes of Health (NIH)
Contact Information
Study Contact:
Interventional Psychiatry
(858) 657-6152
iptrials@health.ucsd.edu
Interventional Psychiatry
(858) 207-0938
iptrials@health.ucsd.edu
UCSD Interventional Psychiatry
Interventions
  • Device: Accelerated Theta Burst Stimulation — B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
Study Locations (1 sites)
UCSD Interventional Psychiatry, San Diego, California 92127 United States
Eligibility Criteria
Inclusion Criteria: 1. 18-70 years old. 2. Diagnosis of major depressive episode, confirmed on Mini-International Neuropsychiatric Interview (MINI), with HRSD score ≥18. 3. Ongoing SI present beyond screening phase of study (confirmed with Beck SSI score ≥4). 4. Pass the TMS adult safety screening (TASS) questionnaire and the MRI safety screening questionnaire. 5. Have failed to achieve a clinical response to an adequate dose of two antidepressants based on an Antidepressant Treatment History Form (ATHF) score for each antidepressant trial of \> 3 in the current episode OR have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF score of 1 or 2 on those 2 separate antidepressants) OR have a combination of one failed trial and one not tolerated trial, per the definitions above. 6. Psychiatric illness due to a general medical condition (GMC) has been ruled out during initial assessment. 7. Voluntary outpatients capable to consent to treatment and seen at the UC San Diego Health Interventional Psychiatry program. 8. Able to adhere to the treatment schedule. Exclusion Criteria: 1. Have a confirmed diagnosis of substance use disorder within the last 3 months. 2. Have a lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms. 3. Have a diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, that is assessed by a study investigator to be primary and causing greater impairment than MDD. 4. Have a diagnosis of any personality disorder, and assessed by a study investigator to be primary and causing greater impairment than MDD. 5. Have SI prompting emergent involuntary hospital stay (SI in which the participant can maintain voluntary and capable outpatient status as well as recent suicide attempt will not be exclusionary). 6. Currently pregnant or lactating, or woman or childbearing age without adequate birth control. 7. Non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview). 8. Not capable to consent to treatment and/or not suitable for outpatient treatment. 9. Have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump; Have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT or a febrile seizure of infancy, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than 5 minutes; Have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed. 10. Currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 900
Locations 19 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multicenter, open-label, non-comparative, non-interventional, observational study to assess te safety and effectiveness of Piqray in the real-world setting

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Piqray — There is no treatment allocation. Patients administered Piqray by prescription will be enrolled.

Primary Outcomes

  • Incidence of AEs (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-06-29
Completion: 2027-05-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Principal Investigators:
  • Novartis Pharmaceuticals (STUDY_DIRECTOR) - Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Novartis Pharmaceuticals
Interventions
  • Other: Piqray — There is no treatment allocation. Patients administered Piqray by prescription will be enrolled.
Study Locations (19 sites)
Novartis Investigative Site, Cheonan Si, Chungcheongnam-do 31116 South Korea
Novartis Investigative Site, Daegu, Dalseo gu 42602 South Korea
Novartis Investigative Site, Goyang-si, Gyeonggi-do 10475 South Korea
Novartis Investigative Site, Suwon, Gyeonggi-do 16499 South Korea
Novartis Investigative Site, Gyeonggi-do, Korea 11765 South Korea
Novartis Investigative Site, Seoul, Korea 02841 South Korea
Novartis Investigative Site, Seoul, Seoul 06351 South Korea
Novartis Investigative Site, Seoul, Seoul 150-713 South Korea
Novartis Investigative Site, Seoul, Yangcheon gu 07985 South Korea
Novartis Investigative Site, Busan, 48108 South Korea
Eligibility Criteria
Inclusion Criteria: Subjects eligible for this study must meet all of the following criteria: 1. Postmenopausal women and men who have a confirmed diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutated, advanced or metastatic breast cancer. 2. Patients who have progressed on prior endocrine based therapy and are going to start Piqray treatment for the first time in accordance with the locally approved label. 3. Patients who are willing to provide written informed consent Exclusion Criteria: Subjects eligible for this study must not meet the following criteria: 1. Patients with contraindication according to prescribing information for Piqray in Korea. \- Severe hypersensitivity to Piqray or to any of its components 2. Female subjects who are pregnant and nursing (lactating) 3. Patients who are sexually active but not willing to follow contraceptive precautions during taking Piqray. 4. Participants who receive or are going to receive any investigational medicine during surveillance period.
Conditions Atrial Fibrillation, Silent Stroke, Cogn...
Phase NA
Enrollment 240
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to assess the effect of the use of neuroprotection in transcutaneous occlusion of the left atrial appendage in patients with atrial fibrillation on the risk of perioperative silent brain ischemia and associated cognitive impairment and depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Procedure: LAAC procedure with the use of transcatheter cerebral protection system — After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.
  • Procedure: LAAC procedure without the use of transcatheter cerebral protection system — Only the aortography through radial access will be done before accessing the left atrium.

Primary Outcomes

  • Change in number of silent cerebral ischemia (SBI) foci (change in the period up to 24 months)
  • Change in volume of silent cerebral ischemia (SBI) foci (change in the period up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-26
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Silesian Centre for Heart Diseases
Collaborators: Leszek Giec Upper-Silesian Medical Centre, Medical University of Silesia, Biostat Sp. z o.o.
Principal Investigators:
  • Zbigniew F Kalarus, Prof. (PRINCIPAL_INVESTIGATOR) - Silesian Centre for Heart Diseases in Zabrze
Contact Information
Study Contact:
Witold A Streb, Ph.D.
0048322713414
w.streb@sccs.pl
Klaudia Rogowska
+48 32 3598313
dyrektor@gcm.pl
Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwesryeteu Medycznego
Wojciech Wojakowski, Prof.
+48 32 252 39 30
wwojakowski@sum.edu.pl
Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwesryeteu Medycznego
Interventions
  • Procedure: LAAC procedure with the use of transcatheter cerebral protection system — After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.
  • Procedure: LAAC procedure without the use of transcatheter cerebral protection system — Only the aortography through radial access will be done before accessing the left atrium.
Study Locations (6 sites)
Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwesryeteu Medycznego, Katowice, 40-635 Poland
Klinika Chorób Serca i Naczyń, Krakowski Szpital Specjalistyczny im. Jana Pawła II, Krakow, 31-202 Poland
I Klinika Kardiologii Katedry Kardiologii UM im. Karola Marcinkowskiego w Poznaniu, Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu, Poznan, 61-848 Poland
Klinika Kardiologii i Chorób Wewnętrznych, Wojskowy Instytut Medyczny, Warsaw, 04-141 Poland
Klinika Choroby Wieńcowej i Strukturalnych Chorób Serca, Narodowy Instytut Kardiologii Stefana kardynała Wyszyńskiego - Państwowy Instytut Badawczy, Warsaw, 04-625 Poland
Silesian Centre for HEart Diseases in Zabrze, Zabrze, 41-800 Poland
Eligibility Criteria
Inclusion Criteria: 1. 18 Years and older 2. Subject able to provide signed informed consent. 3. Documented permanent, persistent, or paroxysmal atrial fibrillation 4. CHA2DS2VASc risk of stroke ≥2 5. At least one of the following criteria: 1. Contraindications to the use of anticoagulants, 2. HSBLED bleeding risk ≥3 Exclusion Criteria: 1. Serious mental diseases, particularly: dementia syndrome of any etiology, schizophrenia,schizoaffective disorders, bipolar disorder 2. History of ischemic stroke 3. Chronic abuse of alcohol or any other psychoactive substances except for nicotine 4. long-term therapy with benzodiazepines 5. The use of antidepressants in 3 months prior inclusion. 6. Previous infections of the central nervous system, including neuroborreliosis 7. Parkinson's disease 8. Huntington's chorea 9. Creutzfeld-Jakob disease 10. Pick's disease 11. Significant atherosclerosis of the cephalic arteries (\> 70% LCCA or the brachiocephalic trunk) 12. Strictures, ectasias, dissection or aneurysms at the exit of the LCCA or the brachiocephalic trunk from the aorta and up to 3 cm above 13. Advancement of vascular changes in DW MRI of the head, grade 3 on the Fazekas scale 14. Presence of a thrombus or tumours of a different nature in the left atrium or its ear 15. Presence of a thrombus in the left ventricle 16. Left atrial appendage anatomy preventing the use of occluders to close the left atrium appendage 17. The presence of mechanical heart valve prostheses 18. The state after the operative closure of the defect in the atrial septum 19. Condition after closing the defect in the interatrial septum with the use of occluders 20. Active infective endocarditis 21. Presence of devices and prostheses that prevent the performance of MRI (pacemakers, clips in the CNS) 22. Status after oesophagal surgery 23. Esophageal diverticula 24. Esophageal varices\> grade 3 25. Allergic to contrast agents 26. A contraindication to use antiplatelet drugs 27. Diagnosis of neoplastic disease with estimated survival beyond 1 year 28. Clininally evident hypothyroidism and hyperthyroidism 29. Klaustrofobia 30. Pregnancy 31. AIDS 32. Participation in other drug research studies 33. The presence of circumstances or any medical condition the Investigator considers problematic for subject inclusion, or test results that may couse problems to provide reliable, acurate to interpretation results
Conditions Vaginal Atrophy, Breast Carcinoma
Phase PHASE3
Enrollment 250
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase III trial compares the effect of vaginal fractional CO2 laser therapy to placebo for the treatment of vaginal dryness in breast cancer survivors with symptoms of genitourinary syndrome of menopause (GSM). Placebo therapy is an inactive treatment that is designed to mimic as closely as possible the active treatment being studied in a clinical trial. In this trial, patients will not be told whether they will be in the laser treatment group or the placebo group until 6-weeks after the third treatment visit (patient-blinded). At that point, patients who received placebo can elect to receive laser treatment similar to the other group. GSM is group of symptoms that affect the female genital and urinary systems and results from the lack of estrogen. Vaginal dryness can be commonly experienced with normal aging, with menopause, or come about from medications used to treat breast cancer such as chemotherapy or endocrine therapies like tamoxifen or aromatase inhibitors. Vaginal fractional CO2 laser therapy may help reduce vaginal dryness. compared to placebo.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Device: Laser Therapy — Undergo vaginal fractional CO2 laser therapy
  • Device: Sham Intervention — Undergo placebo procedure
  • Other: Questionnaire Administration — Ancillary studies
  • Other: Quality of Life Assessment — Ancillary studies

Primary Outcomes

  • Changes in patient reported vaginal dryness severity (Up to 18 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-04-21
Completion: 2027-05
Eligibility
Age: 22 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Maryam Lustberg, MD, MPH (STUDY_CHAIR) - Yale University Comprehensive Cancer Center
Contact Information
Study Contact:
Maryam Lustberg, MD, MPH
(203) 785-4095
Maryam.lustberg@yale.edu
Site Public Contact
MCRCwebsitecontactform@stjoeshealth.org
Trinity Health IHA - Obstetrics and Gynecology West Arbor
Gina B. Long
Trinity Health IHA - Obstetrics and Gynecology West Arbor
Interventions
  • Device: Laser Therapy — Undergo vaginal fractional CO2 laser therapy
  • Device: Sham Intervention — Undergo placebo procedure
  • Other: Questionnaire Administration — Ancillary studies
  • Other: Quality of Life Assessment — Ancillary studies
Study Locations (2 sites)
Trinity Health IHA - Obstetrics and Gynecology West Arbor, Ann Arbor, Michigan 48103 United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Women with a history of breast cancer who have not had exposure to chemotherapy, targeted therapy, immunotherapy and/or radiation) within 3 months prior to registration. * Breast cancer survivors not currently on therapy are eligible * Patients may be receiving ongoing endocrine therapy These patients must be receiving adjuvant endocrine therapy prior to registration and intend to continue the same endocrine therapy for the 4 months while they are receiving protocol treatment, unless a clinically necessary change is indicated at the discretion of the patient's medical oncologist. \* Patients who are receiving endocrine therapy +/- monoclonal therapy like trastuzumab and pertuzumab are eligible * Patients on targeted therapy such as CD4/6 inhibitors are not eligible. Patients receiving concurrent chemotherapy and immunotherapy are not eligible. * Patient-reported vaginal dryness with or without dyspareunia of at least moderate severity on average, defined as \>= 4 on a 0-10-point scale that has been bothersome for \>= 3 months and for which the patient wants to undergo the study procedure * No prior gynecologic cancer, vaginal intra-epithelial neoplasia, pelvic radiation or pelvic reconstructive surgery utilizing mesh. Patients with cervical intraepithelial neoplasia are eligible * No history of scleroderma, lupus, systemic sclerosis, mixed connective tissue disorder, undifferentiated connective tissue disorder or collagen vascular disease, dermatomyositis, polymyositis, lichen sclerosis or vulvar vestibulitis * No pelvic surgery that involved a vaginal incision within 6 months of registration. Patients who received laparoscopic BSO (Bilateral salpingo-oophorectomy) are eligible * No systemic estrogen or progesterone, vaginal estrogen, vaginal prasterone, ospemifene, and/or androgen therapy within 6 weeks prior to registration * No other suspected contraindications for undergoing laser therapy * No prior vaginal laser therapy at any time. Patients who would have completed any type of vaginal laser resurfacing procedure at any time prior to the start of study treatment are not eligible * No known concurrent invasive carcinoma/malignancy. Patients with carcinoma in situ are eligible. Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible if not currently receiving treatment * Postmenopausal based on at least one of the following criteria at the time of registration: * Women 50 or older with no spontaneous regular menses \> 12 months * On ovarian suppression (i.e., gonadotrophin releasing hormone \[GNRH\] agonist/antagonist) for at least 6 months or greater, with plans to continue such treatment for at least 18 weeks * Bilateral oophorectomy * Women on aromatase-inhibitor (AI) therapy (i.e., clinically judged to be postmenopausal) * In order to complete the mandatory patient-completed measures, participants must be able to speak, read and understand English or Spanish * Age \>= 22 years * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * No medical history of: keloid formation, genital fistula, thin recto-vaginal septum (defined as a distance of \< 2 cm between the vaginal opening and the anal opening)